Drugs Stocks On The Rise With Help From 3 Stocks

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 29 points (-0.2%) at 16,714 as of Tuesday, June 3, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,066 issues advancing vs. 1,889 declining with 193 unchanged.

The Drugs industry currently sits down 1.0% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include Theravance ( THRX), down 19.4%, Dr Reddy Laboratories ( RDY), down 2.7%, Allergan ( AGN), down 2.5%, AstraZeneca ( AZN), down 1.2% and GlaxoSmithKline ( GSK), down 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Biomarin Pharmaceutical ( BMRN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Biomarin Pharmaceutical is up $1.74 (3.0%) to $59.74 on average volume. Thus far, 807,280 shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $57.26-$59.99 after having opened the day at $57.77 as compared to the previous trading day's close of $58.00.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $8.5 billion and is part of the health care sector. Shares are down 17.6% year-to-date as of the close of trading on Monday. Currently there are 10 analysts who rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full Biomarin Pharmaceutical Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Amgen ( AMGN) is up $1.14 (1.0%) to $117.59 on light volume. Thus far, 945,040 shares of Amgen exchanged hands as compared to its average daily volume of 3.8 million shares. The stock has ranged in price between $116.20-$117.72 after having opened the day at $116.45 as compared to the previous trading day's close of $116.45.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $87.8 billion and is part of the health care sector. Shares are up 1.7% year-to-date as of the close of trading on Monday. Currently there are 9 analysts who rate Amgen a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $0.98 (1.2%) to $82.53 on light volume. Thus far, 4.3 million shares of Gilead exchanged hands as compared to its average daily volume of 16.8 million shares. The stock has ranged in price between $81.21-$82.82 after having opened the day at $81.27 as compared to the previous trading day's close of $81.55.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $124.7 billion and is part of the health care sector. Shares are up 8.1% year-to-date as of the close of trading on Monday. Currently there are 17 analysts who rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

Ford, GM Gain as China Slashes Auto Import Tariffs

Ford, GM Gain as China Slashes Auto Import Tariffs

U.S. Crude Oil Hits Fresh 3-Year Highs as Gasoline Heads to $3 a Gallon

U.S. Crude Oil Hits Fresh 3-Year Highs as Gasoline Heads to $3 a Gallon